GlassScriptPhysician profile
Linda Le
NPI 1407594484
$423.04
in general payments reported to CMS, 2019-2025
12 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.05 · 2024: $23.64 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $74.72 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $54.66 | 2025 | Airsupra |
| Axsome Therapeutics, INC. | $44.72 | 2025 | Symbravo, Auvelity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.69 | 2022-2024 | Lifevest |
| Astellas Pharma US INC | $37.23 | 2025 | Veozah |
| Novo Nordisk INC | $37.04 | 2025 | Ozempic, Rybelsus |
| Eisai INC. | $29.90 | 2025 | |
| Grifols USA, LLC | $29.57 | 2025 | Prolastin-C Liquid |
| Bioventus LLC | $22.65 | 2025 | Durolane |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $16.89 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $16.56 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.